A Randomized Controlled Trial to study the efficacy of Rasanjanadi Bidalaka and Olopatadine eye drop in Vataja Abhishyanda with reference to Allergic Conjunctivitis

This study aims to evaluate and compare the efficacy of Rasanjanadi Bidalaka, an Ayurvedic topical formulation, and Olopatadine eye drops, a commonly used modern anti-allergic medication, in the management of Vataja Abhishyanda with reference to allergic conjunctivitis. Allergic conjunctivitis is a prevalent ocular condition characterized by symptoms such as itching, redness, watering, foreign body sensation, and photophobia, which significantly affect patient comfort and quality of life. In Ayurvedic literature, Vataja Abhishyanda is described as an ocular disorder with clinical features that closely resemble allergic conjunctivitis, and it is managed through various local therapeutic measures including Bidalaka (application of medicated paste over the eyelids).

This randomized controlled trial is designed to assess the therapeutic effectiveness of Rasanjanadi Bidalaka in comparison with Olopatadine eye drops in reducing the clinical signs and symptoms associated with the condition. Eligible participants diagnosed with Vataja Abhishyanda/allergic conjunctivitis will be randomly allocated into two groups. One group will receive Rasanjanadi Bidalaka as a local Ayurvedic treatment, while the other group will be treated with Olopatadine eye drops as per standard ophthalmic practice. Clinical evaluation will be performed using predefined subjective and objective parameters such as itching, redness, watering, burning sensation, and conjunctival congestion. The changes in symptom severity before and after treatment will be assessed using appropriate scoring systems and statistical analysis to determine the significance of therapeutic outcomes.

The study seeks to explore the potential of a classical Ayurvedic external therapy as an effective and safe alternative or complementary approach in the management of allergic conjunctivitis. By comparing the outcomes with a widely accepted modern pharmacological agent, the trial aims to generate evidence regarding the clinical utility of Rasanjanadi Bidalaka and contribute to the integration of traditional Ayurvedic practices with contemporary ophthalmic care. The findings of this research may help in establishing an economical and accessible treatment option for patients suffering from allergic conjunctivitis while also validating Ayurvedic concepts in the management of ocular disorders